Filtyp
Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.
https://www.createhealth.lth.se/about/recruitment - 2025-12-13
Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ
https://www.createhealth.lth.se/about/partners - 2025-12-13
Lead BiologicsLead Biologics was founded in 2022 by Thoas Fioretos, Carl Sandén and Marcus Järås (Lund University), Kjell Sjöström (Innovagen) and Niklas Landberg (SUS). The company combines state-of-the-art technologies with unique patient cohorts to identify multiple novel therapeutic targets in leukemias and solid tumors. The aim is to develop a first-in-class treatment against SLAMF6. A majors
https://www.createhealth.lth.se/impact/spin-companies - 2025-12-13
The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology
https://www.createhealth.lth.se/canfaster - 2025-12-13
The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &
https://www.createhealth.lth.se/impact/canfaster-publications - 2025-12-13
Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas
Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su
Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye
Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden
https://www.createhealth.lth.se/contact - 2025-12-13
CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic center for translational research focusing on the early diagnosis and prognosis of cancer, as well as the development of novel treatment strategies. Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solut
https://www.createhealth.lth.se/about - 2025-12-13
Our research accompanies the entire patient journey, from initial diagnosis through treatment and companion diagnostics to quality-of-life enhancement during and after cancer. We deliver translational solutions that start from specific clinical needs identified by our clinical partners, leveraging novel technological approaches to accelerate implementation into the clinic with dramatically reduced
https://www.createhealth.lth.se/research - 2025-12-13
Molecular characterisation of breast cancer: biomarkers of risk, prognosis and treatment, Åke Borg, Medical Faculty."The long-term objective is to deepen our understanding of breast cancer etiology through advances in cell biology and molecular genetics, ultimately enabling the development of clinical tools for prognostication, treatment selection, and disease prevention. We systematically investi
https://www.createhealth.lth.se/research/research-projects - 2025-12-13
Please wait...
https://www.createhealth.lth.se/contact/principal-investigators - 2025-12-13
In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are distributed over a five-year period and dedicated to translational cancer research within the L2CancerBridge program.Other previous and current funding for the CREA
https://www.createhealth.lth.se/about/funding - 2025-12-13
L2CancerBridge is a groundbreaking collaborative cancer research program that bridges two of Europe's leading research institutions: CREATE Health at Lund University, Sweden, and the Swiss Cancer Centre at EPFL in Lausanne, Switzerland. The L2CancerBridge program exemplifies how international partnerships can accelerate cancer research breakthroughs. By combining the expertise and resources of Swe
https://www.createhealth.lth.se/research/l2cancerbridge-program-collaborative-excellence - 2025-12-13
Please wait...
https://www.createhealth.lth.se/contact/antibody-unit - 2025-12-13
Antibody Initiative Advances in antibody engineering have revolutionised cancer therapy, and biological drugs now constitute a cornerstone of frontline treatment across most cancer subtypes. We drive continued innovation and clinical success by continuously enhancing local capabilities in Lund to develop tailored molecules for targeted cancer treatment- specific antigens, immune checkpoints, or as
https://www.createhealth.lth.se/research/technologies - 2025-12-13
Denna karta som pdf (246 kB, ny flik). Rum på våning 1 SALTO i E-husetE:AE:BLED-CafeGlasverandanE:1144E:1145E:1147E:1149E:1147-49E:1123E:1124E:1328E:1406E:1407E:1426E:1517aE:LÄSALÄSAE:TYSTATYSTAVåning 0Våning 2Våning 3Våning 4Våning 5Översiktskarta
https://www.ehuset.lth.se/e1124 - 2025-12-13
Denna karta som pdf (3,3 MB, ny flik). Rum på våning 1 SALTO i E-husetE:AE:BLED-CafeGlasverandanE:1144E:1145E:1147E:1149E:1147-49E:1123E:1124E:1328E:1406E:1407E:1426E:1517aE:LÄSALÄSAE:TYSTATYSTAVåning 0Våning 2Våning 3Våning 4Våning 5Översiktskarta
https://www.ehuset.lth.se/e1328 - 2025-12-13
Denna karta som pdf (248 kB, ny flik). Rum på våning 1 SALTO i E-husetE:AE:BLED-CafeGlasverandanE:1144E:1145E:1147E:1149E:1147-49E:1123E:1124E:1328E:1406E:1407E:1426E:1517aE:LÄSALÄSAE:TYSTATYSTAVåning 0Våning 2Våning 3Våning 4Våning 5Översiktskarta
https://www.ehuset.lth.se/e1406 - 2025-12-13
